Vaste dosissen

Continuous manufacturing

GEA and its partners are leading the way toward smaller, more flexible, continuous processing technologies that have the potential to transform the future of pharmaceutical development and manufacturing … and deliver customized quantities of drugs to patients in need in a quick and efficient way. ConsiGma® 4.0 is the next step in that journey.

ConsiGma 4.0

ConsiGma® 4.0: Next-generation continuous pharmaceutical manufacturing

GEA believes that continuous processing improves the quality of pharmaceutical end products by focusing on quality during the whole product lifecycle, not just “tested in” quality, and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.

Moreover, the company also feels that CM equipment should be available to all pharmaceutical companies: Ethicals, Generics (global as well as regional), OTC, CMO/CDMO/CRO and Nutraceutical manufacturers. By taking a more holistic and inclusive stance as a trusted supplier to the pharmaceutical industry, the company can now deliver an unparalleled combination of highly effective, flexible and cost-efficient production solutions to a wider and more diverse array of companies.

Based on three key pillars, the multipurpose ConsiGma® 4.0 platform — designed to transfer powder into coated tablets in development, pilot, clinical and production volumes — can now be supplied as

  • a fully integrated line
  • standalone plant for dedicated “bin-to-bin” unit operations 
  • a combination of modules that can be installed in both new and existing facilities with selected and qualified third-party machiner

GEA can provide top-of-the-range, fully configurable manufacturing systems that convert powder into coated tablets in a single line, as well as customer-specific equipment that can be integrated with existing plant. Irrespective of the size or scale of your CM implementation strategy, GEA’s SCADA-compliant ConsiGma® “Conductor 4.0” control software facilitates the integration and consolidation of independent unit operations.

ConsiGma® 4.0 = industry 4.0

The pharma manufacturing landscape is evolving as never before. Much of this change is being driven by greater connectivity and Industry 4.0 — the fourth industrial revolution. Continuous manufacturing and is an enabler of both digitalization and the industrial Internet of Things (IIoT). ConsiGma® 4.0 makes it possible to gather and analyze real-time data, speed up production processes and run more efficient manufacturing lines that deliver higher-quality goods at a reduced cost. It will help you to optimize your quality assurance procedures, offer higher levels of process transparency and control your entire supply chain within tight tolerances, resulting in improved productivity, increased Overall Equipment Effectiveness (OEE) and enhanced real-time planning and scheduling.

Learn more about ConsiGma® continuous processing

Producten & technologieën

{{count}} van {{total}} wordt weergegeven

Blijf op de hoogte van GEA’s innovaties en verhalen door u in te schrijven op nieuws van GEA.


Wij zijn er om u te helpen! Met slechts een paar gegevens kunnen we uw vraag beantwoorden.

Stel uw vraag